Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006399 · ClinicalTrials.gov registry record · Phase 2
Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease
A Phase 2 study, sponsored by National Center for Research Resources (NCRR).
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT00006399 is a Phase 2 study that has completed, run by National Center for Research Resources (NCRR). The registered enrollment target is 45 participants.
The verdict
NCT00006399, a Phase 2 study, has completed, sponsored by National Center for Research Resources (NCRR).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
The goal of this study is to examine whether the administration of estrogen to post-menopausal women and women with mild to moderate Alzheimer's disease will enhance their memory and their capacity for learning.
Interventions
- DRUG Progesterone
- DRUG Estrogen
- DRUG Donepezil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 1999-09 |
| Est. Completion | 2004-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006399
The ClinicalTrials.gov registry entry for NCT00006399 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Center for Research Resources (NCRR), which has 94 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Progesterone is the first listed.
NCT00006399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006399 about?
NCT00006399 is a clinical study titled "Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease". The goal of this study is to examine whether the administration of estrogen to post-menopausal women and women with mild to moderate Alzheimer's disease will enhance their memory and their capacity for learning.
What is the current status of trial NCT00006399?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 1999-09. Estimated completion is 2004-03.
What interventions are being tested in trial NCT00006399?
The interventions under investigation include: Progesterone (DRUG), Estrogen (DRUG), Donepezil (DRUG).
Who is sponsoring clinical trial NCT00006399?
This trial is sponsored by National Center for Research Resources (NCRR), which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.